The current valuation score of Eterna Therapeutics Inc is 9.23, ranking 46 out of 384 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.02, which is -232.67% below the recent high of 0.03 and -17216.34% above the recent low of -3.50.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.